MGRM vs. ANGO, UTMD, DCTH, RCEL, TLSI, OBIO, DRTS, CLPT, CVRX, and ARAY
Should you be buying Monogram Orthopaedics stock or one of its competitors? The main competitors of Monogram Orthopaedics include AngioDynamics (ANGO), Utah Medical Products (UTMD), Delcath Systems (DCTH), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), Alpha Tau Medical (DRTS), ClearPoint Neuro (CLPT), CVRx (CVRX), and Accuray (ARAY). These companies are all part of the "surgical & medical instruments" industry.
Monogram Orthopaedics (NASDAQ:MGRM) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
0.5% of Monogram Orthopaedics shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 32.1% of Monogram Orthopaedics shares are held by company insiders. Comparatively, 5.1% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Monogram Orthopaedics has a net margin of 0.00% compared to AngioDynamics' net margin of -60.21%. AngioDynamics' return on equity of -3.48% beat Monogram Orthopaedics' return on equity.
In the previous week, AngioDynamics had 8 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 10 mentions for AngioDynamics and 2 mentions for Monogram Orthopaedics. Monogram Orthopaedics' average media sentiment score of 0.43 beat AngioDynamics' score of 0.21 indicating that Monogram Orthopaedics is being referred to more favorably in the media.
Monogram Orthopaedics has higher earnings, but lower revenue than AngioDynamics. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
AngioDynamics received 362 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users.
AngioDynamics has a consensus target price of $13.25, indicating a potential upside of 109.98%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than Monogram Orthopaedics.
Summary
AngioDynamics beats Monogram Orthopaedics on 9 of the 15 factors compared between the two stocks.
Get Monogram Orthopaedics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monogram Orthopaedics Competitors List
Related Companies and Tools
